序号 |
标题 |
次数 |
作者 |
发布时间 |
75916 |
AcLys-PABC-VC-Aur0101, cas:1438851-17-2,ADC定制 |
135 |
wyh |
2024-12-19 |
75917 |
cas:107348-47-0,2,5-dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate ADC抗体偶联药物 |
74 |
zyl |
2024-12-19 |
75918 |
SMCC-DM4 , cas:1228105-52-9,ADC定制 |
78 |
wyh |
2024-12-19 |
75919 |
cas:1639939-40-4 Mal-Val-Ala-PAB-PNP |
78 |
zyl |
2024-12-19 |
75920 |
MA-PEG8-VA-PAB-SG3199,ADC定制 |
95 |
wyh |
2024-12-19 |
75921 |
Acid-PEG4-Val-Cit-PAB-MMAE |
70 |
zyl |
2024-12-19 |
75922 |
MC-Val-Cit-PAB-Indibulin,cas:2055896-95-0,ADC定制 |
86 |
wyh |
2024-12-19 |
75923 |
cas:1096584-62-1 Mal-Val-Cit-PAB-PNP |
83 |
zyl |
2024-12-19 |
75924 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
82 |
zyl |
2024-12-19 |
75925 |
MC-Sq-Cit-PAB-Dolastatin10 ,cas:1941168-65-5,ADC定制 |
97 |
wyh |
2024-12-19 |
75926 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
90 |
zyl |
2024-12-19 |
75927 |
N3-PEG4-DYKDDDD-Doxorubicin,ADC定制 |
107 |
wyh |
2024-12-19 |
75928 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
69 |
zyl |
2024-12-19 |
75929 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
92 |
zyl |
2024-12-19 |
75930 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
89 |
zyl |
2024-12-19 |
75931 |
MC-GGFG-DX8951 cas:1600418-29-8 |
78 |
zyl |
2024-12-19 |
75932 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
96 |
h |
2024-12-19 |
75933 |
N3-PEG4-vc-PAB-Doxorubicin 叠氮PEG修饰维生素C-阿霉素的介绍 |
191 |
zyl |
2024-12-19 |
75934 |
DOTA-Ahx-(d-Lys6-GnRH1)DOTA偶联的d-Lys6-GnRH肽 |
91 |
h |
2024-12-19 |
75935 |
DOTA-porphyrin 双功能螯合剂DOTA偶联5-(对-氨基-丙烯-氧苯基)-10,15,20-三-(对-羧基-甲基-烯-氧苯基)卟啉 |
122 |
h |
2024-12-19 |
75936 |
VC-SECO DUBA analogue,ADC定制 |
94 |
wyh |
2024-12-19 |
75937 |
DOTA-H-Lys(Boc)-OH-SWCNTs 赖氨酸胺手柄功能化的单壁碳纳米管偶联DOTA螯合剂 |
91 |
h |
2024-12-19 |
75938 |
[DOTA-A1]-ZHER2:S1 抗HER2 ZHER2:S1亲和体分子缀合DOTA |
125 |
h |
2024-12-19 |
75939 |
Vc-MMAD cas:1401963-17-4的结构式 |
77 |
zyl |
2024-12-19 |
75940 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
101 |
h |
2024-12-19 |
75941 |
CL2A-SN38,cas:1279680-68-0,ADC定制 |
171 |
wyh |
2024-12-19 |
75942 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
77 |
h |
2024-12-19 |
75943 |
DOTA-GSG-KCCYSL DOTA缀合物ErbB-2靶向肽KCCYSL |
155 |
h |
2024-12-19 |
75944 |
MC-MMAF , cas:863971-19-1,ADC定制 |
115 |
wyh |
2024-12-19 |
75945 |
TCO-PEG4-Fmoc-Gly-Gly-Gly-ADC连接子 |
137 |
zyl |
2024-12-19 |
75946 |
模拟肽4-[2-(3,4,5,6-四氢嘧啶-2-基氨基)乙氧基]苯甲酰基-2-[N-(3-氨基-新戊-1-氨基甲酰基)]-氨乙基磺酰基-氨基-β-丙氨酸(IAC)缀合DOTA |
90 |
h |
2024-12-19 |
75947 |
DOTA-chCE7 DOTA标记的糖基化单克隆抗L1-CAM抗体chCE7 |
100 |
h |
2024-12-19 |
75948 |
Vc-MMAE, cas:646502-53-6,ADC定制 |
133 |
wyh |
2024-12-19 |
75949 |
Azido-PEG4-MMAE |
116 |
zyl |
2024-12-19 |
75950 |
cas:2055024-59-2,Fmoc-PEG2-Val-Cit-PAB-OH |
117 |
zyl |
2024-12-19 |
75951 |
Azide-PEG6-Val-Cit-PAB-PEG6- Biotin,ADC定制 |
120 |
wyh |
2024-12-19 |
75952 |
Ga-DOTA-(Asp)n 大环DOTA共轭(Asp)n肽 |
71 |
h |
2024-12-19 |
75953 |
cas:1807530-16-0,2-hydroxyethyl disulfide mono-Tosylate- ADC linker |
90 |
zyl |
2024-12-19 |
75954 |
DOTA偶联受体特异性肽 |
116 |
h |
2024-12-19 |
75955 |
聚乙二醇化DOTA-AHA基GdIII螯合物 PEGylated DOTA-based gadolinium(III) |
99 |
h |
2024-12-19 |
75956 |
PAMAM树状大分子DOTA缀合物 PAMAM–DOTA |
100 |
h |
2024-12-19 |
75957 |
ALD-tetra-EG-Osu的介绍 |
123 |
zyl |
2024-12-19 |
75958 |
SSTR2靶向肽Tyr(3)-奥曲肽(tate) |
223 |
h |
2024-12-19 |
75959 |
DOTA-D-Phe(1)-Tyr(3)-Octreotide |
94 |
h |
2024-12-19 |
75960 |
cas:55750-63-5,Mal-heptanoic NHS ester |
113 |
zyl |
2024-12-19 |